Clinical Trials · NCT05445232
A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 32
- Start date
- Jul 2022
- Locations
- 2 sites, United States
- Primary endpoint
- Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Midazolam